Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Article in Chinese | MEDLINE | ID: mdl-21186536

ABSTRACT

OBJECTIVE: To observe the efficacy and safety of PEG-interferon alpha-2a (PEG-IFNalpha-2a) treatment on lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients. METHODS: Eighty-one patients with lamivudine-resistant HBeAg (+) chronic hepatitis B patients were enrolled and divided into PEG-IFNalpha-2a treatment group (40 cases) and adefovir dipivoxil (ADV) control group (41 cases). Two groups were combined with LAM in the first 12 weeks(w). The ALT normalization rate, the HBV DNA and HBeAg negative rate, and the HBeAg seroconversion rate were observed in 12 W, 24 W, 48 W. RESULTS: The ALT normalization rate in 12 W, 24 W of PEG-IFNalpha-2a group was 62.5% and 80.0%. And it was higher than that of ADV group. The HBeAg negative rate and HBeAg seroconversion rate in 48 W of PEG-IFNalpha-2a group were 60% and 57.5% , which were higher than that of ADV group. The difference was statistically significant (P < 0.05). CONCLUSION: PEG-IFNalpha-2a treatment of lamivudine-resistant HBeAg (+) chronic hepatitis B is superior to ADV, and its security is well.


Subject(s)
Antiviral Agents/therapeutic use , DNA, Viral/analysis , Drug Resistance, Viral/genetics , Hepatitis B, Chronic/drug therapy , Interferon-alpha/therapeutic use , Lamivudine/therapeutic use , Polyethylene Glycols/therapeutic use , Adenine/analogs & derivatives , Adenine/therapeutic use , Adult , DNA, Viral/drug effects , Drug Resistance, Viral/drug effects , Female , Hepatitis B virus/drug effects , Hepatitis B, Chronic/virology , Humans , Interferon alpha-2 , Interferons/immunology , Interferons/pharmacology , Male , Middle Aged , Mutation , Organophosphonates/therapeutic use , Recombinant Proteins , Treatment Outcome , Watchful Waiting
2.
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue ; 16(8): 487-90, 2004 Aug.
Article in Chinese | MEDLINE | ID: mdl-15298810

ABSTRACT

OBJECTIVE: To assess the effectiveness of molecular adsorbent recirculation system (MARS) to remove nitric oxide(NO) and cytokines in multiple organ dysfunction syndrome(MODS) in patients with severe liver failure. METHODS: Single MARS treatment were performed for 198 times with duration ranging from 6 to 24 hours on 61 MODS patients (42M/19F). The efficacy was evaluated by sequential organ failure assessment, biochemical parameters and the levels of pro-inflammatory cytokines. RESULTS: The MARS therapy resulted in a significant removal of NO and certain cytokines such as tumor necrosis factor-alpha(TNF-alpha), interleukin-2(IL-2), IL-6, IL-8, and lipopolysaccharide-binding protein(LBP), together with marked reduction of other non-water soluble albumin bound toxins and water soluble toxins. These were associated with an improvement of the patients' clinical conditions, including deranged hemodynamics, respiratory function, cardiovascular and renal functions, hepatic encephalopathy, thus resulting in a marked decrease of sequential organ failure assessment(SOFA) score and improved outcome. Twenty-five patients were able to be discharged from the hospital, and successful liver transplantation could be performed in 6 patients. The overall survival rate of 61 patients was 41.0%. CONCLUSION: MARS could be used for the treatment of MODS patients associated with elevated levels of NO and cytokines with satisfactory results.


Subject(s)
Liver, Artificial , Multiple Organ Failure/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Cytokines/metabolism , Female , Humans , Male , Middle Aged , Multiple Organ Failure/blood , Nitric Oxide/metabolism , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...